Comerford M B, Besterman E M
Postgrad Med J. 1976 Aug;52(610):481-6. doi: 10.1136/pgmj.52.610.481.
Following an initial dose response study, metoprolol, a selective beta1-receptor blocking agent, was compared with equipotent dosages of propanolol in a double blind cross-over study, including exercise tolerance tests, on fourteen patients with angina pectoris. Long term therapy with metoprolol then followed until the seventy-second week. Patients performed 8% more total work on metoprolol with 15% more work recorded up to the onset of S-T depression, in comparison with propranolol. In the long term, ther was no significant difference in work performed when the daily dosage of metoprolol was changed from a q.i.d. to a b.d. regime. Metoprolol was shown to be an effective anti-anginal compound with good tolerance and safety, with gradual improvement in underlying myocardial ischaemia during long term treatment.
在一项初始剂量反应研究之后，在一项双盲交叉研究中，将选择性β1受体阻滞剂美托洛尔与等效剂量的普萘洛尔进行了比较，该研究包括对14名心绞痛患者的运动耐量测试。随后进行了美托洛尔的长期治疗，直至第72周。与普萘洛尔相比，患者服用美托洛尔时的总工作量增加了8%，在S-T段压低发作前记录的工作量增加了15%。从长期来看，当美托洛尔的每日剂量从每日四次改为每日两次时，所完成的工作量没有显著差异。美托洛尔被证明是一种有效的抗心绞痛化合物，具有良好的耐受性和安全性，在长期治疗期间基础心肌缺血状况逐渐改善。
